NO20052264L - Pregabalinderivater for behandling av fibromyalgi og andre forstyrrelser - Google Patents

Pregabalinderivater for behandling av fibromyalgi og andre forstyrrelser

Info

Publication number
NO20052264L
NO20052264L NO20052264A NO20052264A NO20052264L NO 20052264 L NO20052264 L NO 20052264L NO 20052264 A NO20052264 A NO 20052264A NO 20052264 A NO20052264 A NO 20052264A NO 20052264 L NO20052264 L NO 20052264L
Authority
NO
Norway
Prior art keywords
carbon atoms
linear
fibromyalgia
agoraphobia
disorders
Prior art date
Application number
NO20052264A
Other languages
English (en)
Norwegian (no)
Other versions
NO20052264D0 (no
Inventor
David Juergen Wustrow
Jr Charles Price Taylor
Andrew John Thorpe
David James Dooley
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32600153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20052264(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO20052264D0 publication Critical patent/NO20052264D0/no
Publication of NO20052264L publication Critical patent/NO20052264L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20052264A 2002-12-13 2005-05-10 Pregabalinderivater for behandling av fibromyalgi og andre forstyrrelser NO20052264L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43349102P 2002-12-13 2002-12-13
US48774003P 2003-07-16 2003-07-16
PCT/IB2003/005712 WO2004054566A1 (fr) 2002-12-13 2003-12-03 Derives de pregabalin pour le traitement de la fibromyalgie et d'autres troubles

Publications (2)

Publication Number Publication Date
NO20052264D0 NO20052264D0 (no) 2005-05-10
NO20052264L true NO20052264L (no) 2005-09-12

Family

ID=32600153

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052264A NO20052264L (no) 2002-12-13 2005-05-10 Pregabalinderivater for behandling av fibromyalgi og andre forstyrrelser

Country Status (15)

Country Link
US (1) US20090203782A1 (fr)
EP (2) EP2172197A1 (fr)
JP (1) JP2006513257A (fr)
KR (1) KR20050085636A (fr)
CN (1) CN101862317A (fr)
AU (1) AU2003303040B2 (fr)
BR (1) BR0317253A (fr)
CA (1) CA2505788A1 (fr)
MX (1) MXPA05006320A (fr)
NO (1) NO20052264L (fr)
NZ (1) NZ540591A (fr)
PL (1) PL377520A1 (fr)
RU (2) RU2353358C2 (fr)
TW (1) TW200423925A (fr)
WO (1) WO2004054566A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050119676A (ko) * 2003-03-31 2005-12-21 제노포트 인코포레이티드 가바 유사체의 프로드러그를 사용한 열성 홍조의 치료 또는예방
JP2007505095A (ja) * 2003-09-12 2007-03-08 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー うつ病及び不安障害の治療のためのアルファ−２−デルタリガンド及びｓｓｒｉ及び／又はｓｎｒｉを含む組み合わせ
US20070141684A1 (en) 2005-12-21 2007-06-21 Pfizer Inc Preparation of gamma-amino acids having affinity for the alpha-2-delta protein
WO2015117147A1 (fr) 2014-02-03 2015-08-06 Quadriga Biosciences, Inc. Acides bêta-aminés substitués en bêta et analogues en tant qu'agents de chimiothérapie
BR112016017993A2 (pt) 2014-02-03 2017-08-08 Quadriga Biosciences Inc Gama-aminoácidos beta-substituídos e análogos como agentes quimioterapêuticos
KR20180035894A (ko) 2015-08-03 2018-04-06 콰드리가 바이오사이언시스 인코포레이티드 화학치료제로서의 베타-치환된 베타-아미노산 및 유사체 및 이들의 용도
CN115739134B (zh) * 2022-11-24 2024-08-02 贵州大学 一种利用三氯化钌废弃物制备氯乙烯合成用复合催化剂的方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
HU222776B1 (hu) 1992-05-20 2003-10-28 Northwestern University (S)-(+)-4-amino-3-(2-metil-propil)-butánsav előállításának új hexánsav- és butándisav-származék köztitermékei és ezek előállítása
CZ284157B6 (cs) 1992-12-17 1998-08-12 Pfizer Inc. Pyrazolové a pyrazolopyrimidinové sloučeniny jako takové a pro léčbu chorob a farmaceutické prostředky na jejich bázi
TW370529B (en) 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
TW336932B (en) 1992-12-17 1998-07-21 Pfizer Amino-substituted pyrazoles
KR19990067704A (ko) 1992-12-17 1999-08-25 디. 제이. 우드, 스피겔 알렌 제이 부신피질자극호르몬 유리인자 길항제로서의 피롤로피리미딘을함유하는 약학 조성물
RU2130453C1 (ru) 1992-12-17 1999-05-20 Пфайзер Инк. Замещенные пиразолы, фармацевтическая композиция на их основе, способ лечения, промежуточный продукт
US5670539A (en) * 1993-07-21 1997-09-23 New York State Office Of Mental Health Treatment of movement disorders using large neutral amino acids
US6372792B1 (en) * 1996-04-26 2002-04-16 Guy Chouinard Method for treating anxiety, anxiety disorders and insomnia
PL189872B1 (pl) * 1996-07-24 2005-10-31 Warner Lambert Co Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu
SE9603408D0 (sv) * 1996-09-18 1996-09-18 Astra Ab Medical use
WO1998017627A1 (fr) 1996-10-23 1998-04-30 Warner-Lambert Company Acides aminobutyriques gamma substitues utilises comme agents pharmaceutiques
US6127418A (en) * 1997-08-20 2000-10-03 Warner-Lambert Company GABA analogs to prevent and treat gastrointestinal damage
HUP0004310A3 (en) 1997-10-27 2001-11-28 Warner Lambert Co Cyclic amino acids, and derivatives thereof and pharmaceutical compositions comprising the said compounds as active agents
JP2002520277A (ja) 1998-07-09 2002-07-09 ワーナー−ランバート・カンパニー 不眠症を治療する方法
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DK1169060T3 (da) * 1999-04-09 2006-01-16 Euro Celtique Sa Natriumkanalblokkerpræparater og anvendelse deraf
RS50352B (sr) 1999-06-10 2009-11-10 Warner-Lambert Company Llc., Monosupstituisane 3-propil gama-aminobuterne kiseline
US7164034B2 (en) * 1999-06-10 2007-01-16 Pfizer Inc. Alpha2delta ligands for fibromyalgia and other disorders
US6642398B2 (en) * 1999-06-10 2003-11-04 Warner-Lambert Company Mono-and disubstituted 3-propyl gamma-aminobutyric acids
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
ES2287021T3 (es) * 1999-07-22 2007-12-16 University Of Rochester Metodo para el tratamiento de sintomas de variacines hormonales que incluyen el fogaje.
US6281207B1 (en) * 1999-09-15 2001-08-28 Reed Richter Treatment of movement disorders by administration of mirtazapine
HN2000000224A (es) 1999-10-20 2001-04-11 Warner Lambert Co Aminoacidos biciclicos como agentes farmaceuticos
GB2362646A (en) 2000-05-26 2001-11-28 Warner Lambert Co Cyclic amino acid derivatives useful as pharmaceutical agents
GB2365425A (en) * 2000-08-01 2002-02-20 Parke Davis & Co Ltd Alkyl amino acid derivatives useful as pharmaceutical agents
US20020099013A1 (en) * 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
IL145584A0 (en) * 2000-10-02 2002-06-30 Pfizer Prod Inc Nmda nr2b antagonists for treatment
US20020165246A1 (en) * 2001-03-05 2002-11-07 Andrew Holman Administration of sleep restorative agents
DE60213592T2 (de) * 2001-05-25 2007-08-09 Warner-Lambert Co. Llc Flüssige pharmazeutische zusammensetzung

Also Published As

Publication number Publication date
EP1572188A1 (fr) 2005-09-14
RU2353358C2 (ru) 2009-04-27
PL377520A1 (pl) 2006-02-06
EP2172197A1 (fr) 2010-04-07
JP2006513257A (ja) 2006-04-20
TW200423925A (en) 2004-11-16
US20090203782A1 (en) 2009-08-13
KR20050085636A (ko) 2005-08-29
MXPA05006320A (es) 2005-08-26
WO2004054566A1 (fr) 2004-07-01
NZ540591A (en) 2008-03-28
CN101862317A (zh) 2010-10-20
AU2003303040B2 (en) 2009-04-23
RU2008140653A (ru) 2010-04-20
CA2505788A1 (fr) 2004-07-01
BR0317253A (pt) 2005-11-01
AU2003303040A1 (en) 2004-07-09
RU2005118081A (ru) 2006-01-20
NO20052264D0 (no) 2005-05-10

Similar Documents

Publication Publication Date Title
RU2405774C2 (ru) Гетероциклические ингибиторы аспартилпротеазы
DE60325830D1 (de) Substituiertes phenylalkansäurederivat und dessen verwendung
NO20052580L (no) Blandinger for behandling av infeksjon av Flavivirida viruser
EA201070202A1 (ru) Производное оксопиразина и гербицид
DE602004003389D1 (de) Verfahren zur herstellung von 4'-azidonukleosidderivaten
CA2315262A1 (fr) Composes des cyclopentane et cyclopentene convenant comme inhibiteurs de neuraminidase
NZ705710A (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
BR9509212A (pt) Composto composição farmacêutica método de inibição de prostaglandina H sintase em um mamífero método de tratamento de uma doença inflamatória em um mamífero e método de tratamento de pirese em um mamífero
BR0208805A (pt) Uso de um derivado de pirazolina
NO20091858L (no) Hydrobenzamid derivater som inhibitorer av HSP90
ATE264311T1 (de) Verbindungen zur behandlung und vorsorge bei diabetes
DE60237128D1 (de) Verfahren zur Herstellung von Isopulegol
NO20052264L (no) Pregabalinderivater for behandling av fibromyalgi og andre forstyrrelser
NO20010487L (no) Disubstituert maleimidforbindelse og farmasøytisk anvendelse herav
WO2004031160A3 (fr) Composes derives de la 2-thiohydantoïne et leur utilisation pour le traitement du diabete
BR0311338A (pt) Derivados de n-acilaminobenzeno como inibidores seletivos da monoamina oxidade b
BR8202861A (pt) Composto composicao farmaceutica processo para baixar a pressao sanguinea de seres humanos processo para preparar um composto e process para preparar uma composicao farmaceutica
BR0311719A (pt) Fluorobenzamidas
EA200100640A1 (ru) Ингибиторы вирусов герпеса, представляющие собой ацетамид и замещенные ацетамидосодержащие тиомочевины
NO971687D0 (no) Diazepinoindoler som forsfodiesterase IV-inhibitorer
EP1147772A4 (fr) Compositions medicamenteuses utilisees dans le traitement de la fibrillation auriculaire
MXPA05008706A (es) 4-[(2, 4- dicloro-5 -metoxifenil) amino]-6 -alcoxi -3- quinolincarbonitrilos para tratamiento de lesiones isquemicas.
EA200100631A1 (ru) Ингибиторы вирусов герпеса, представляющие собой гетероциклические карбоксамидсодержащие тиомочевины, имеющие фенилендиаминогруппу
EA200100634A1 (ru) Тиомочевинные ингибиторы вирусов герпеса
DE602004019778D1 (de) Verwendung von 2-amino-1,3-propandiolderivaten zur herstellung eines medikaments zur behandlung von bestimmten schmerzen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application